PAFAH1B3 and neoplasm: Based on the results of the CellMiner analysis, which allowed us to identify nine tumor-sensitive drugs (Fig. 5A), Milciclib had lower IC50 values in patients with high PAFAH1B3 expression (Fig. 5B).